Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy 24th Annual Meeting

Rhea-AI Summary

Decibel Therapeutics (Nasdaq: DBTX) announced its participation in the ASGCT 24th Annual Meeting, with two digital presentations scheduled for May 11, 2021. The presentations will feature data on DB-OTO, a gene therapy developed in collaboration with Regeneron Pharmaceuticals to address otoferlin gene deficiencies in children. Key details include:

• Abstract 579: Focuses on preclinical data for DB-OTO.
• Abstract 536: Discusses AAV toxicity mechanisms in the ear.

Decibel aims to transform treatments in hearing and balance, addressing significant unmet medical needs.

BOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that it will present two digital presentations at the American Society of Gene and Cell Therapy (ASGCT) 24^th Annual Meeting, to be held virtually May 11-14, 2021. The digital presentations will highlight Decibel’s innovative platform and provide data on DB-OTO, Decibel’s gene therapy being developed in collaboration with Regeneron Pharmaceuticals to restore hearing in children with a deficiency in the otoferlin gene.

Presentation details are as follows:

Abstract number: 579
Title: Development of an AAV-Based Gene Therapy for Children with Congenital Hearing Loss Due to Otoferlin Deficiency (DB-OTO)
Summary: An overview of preclinical DB-OTO data from mice and non-human primates
Date and time: Tuesday May 11, 2021, 8:00 a.m. – 10:00 a.m. ET

Abstract number: 536
Title: Mechanisms of Promoter-Driven AAV Toxicity in the Ear
Summary: An overview of potential mechanisms of ubiquitous promoter-driven AAV toxicity in the ear
Date and time: Tuesday May 11, 2021, 8:00 a.m. – 10:00 a.m. ET

About Decibel Therapeutics
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all.

Investor Contact:
Julie Seidel
Stern Investor Relations, Inc.
julie.seidel@sterinir.com
212-362-1200

Media Contact:
Chris Railey
Ten Bridge Communications
chris@tenbridgecommunication.com
617-834-0936

FAQ

What is Decibel Therapeutics presenting at the ASGCT meeting?

Decibel Therapeutics is presenting two digital presentations focused on their gene therapy DB-OTO and AAV toxicity mechanisms on May 11, 2021.

What is DB-OTO and its significance?

DB-OTO is a gene therapy developed by Decibel Therapeutics in collaboration with Regeneron to address congenital hearing loss due to otoferlin deficiency in children.

When will Decibel's presentations take place at ASGCT?

The presentations are scheduled for May 11, 2021, from 8:00 a.m. to 10:00 a.m. ET.

What data will be presented regarding DB-OTO?

The presentation will provide an overview of preclinical DB-OTO data from studies conducted on mice and non-human primates.

What are the abstract numbers for Decibel's presentations?

The abstract numbers are 579 for DB-OTO and 536 for AAV toxicity mechanisms.